Are Inflammatory Biomarkers Increased in Varicose Vein Blood?

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 7, 2016, Pages 656-664

  Lattimer, Christopher R ^a   Kalodiki, Evi ^a   Geroulakos, George ^a,b   Hoppensteadt, Debra ^b   Fareed, Jawed ^b  

^a EALING HOSPITAL   (United Kingdom)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

biochip array analysis; chronic venous insufficiency; inflammatory biomarkers; inflammatory cytokines; varicose veins

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; VASCULOTROPIN; CYTOKINE;

ADULT; AGE; AGED; ARTICLE; BIOCHIP ARRAY METHOD; CHRONIC VEIN INSUFFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUESTIONNAIRE; SAPHENOUS VEIN; VARICOSIS; BLOOD; CHRONIC DISEASE; MIDDLE AGED; VEIN INSUFFICIENCY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; VARICOSE VEINS; VENOUS INSUFFICIENCY;

EID: 84984869319     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616645330     Document Type: Article

References (41)

1. Reeder SW, Wolff O, Partsch H, et al. Expert consensus document on direct ambulatory venous pressure measurement. Int Angiol. 2013; 32 (5): 453-458.
2. Amsler F, Rabe E, Blattler W,. Leg symptoms of somatic, psychic, and unexplained origin in the population-based Bonn vein study. Eur J Vasc Endovasc Surg. 2013; 46 (2): 255-262.
3. Signorelli SS, Malaponte MG, Di Pino L, Costa MP, Pennisi G, Mazzarino MC,. Venous stasis causes release of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha) by monocyte-macrophage. Clin Hemorheol Microcirc. 2000; 22 (4): 311-316.
4. Satokawa H, Hoshino T, Igari F, Iwaya F, Midorikawa H,. The appearance of cytokines and adhesion molecules in saphenous vein valves in chronic venous insufficiency. Phlebology. 2002; 16 (3): 106-110.
5. Yasim A, Kilinc M, Aral M, et al. Serum concentration of procoagulant, endothelial and oxidative stress markers in early primary varicose veins. Phlebology. 2008; 23 (1): 15-20.
6. Tisato V, Zauli G, Rimondi E, et al. Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells. Hindawi publishing corporation Mediators of Inflammation Article ID 423407. Web site. http://dx.doi.org/10.1155/2013/423407. Accessed April 12, 2016:1-13.
7. Tisato V, Zauli G, Gianesini S, et al. Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction. Hindawi publishing corporation J Immunol Res Article ID 473765. Web site. http://dx.doi.org/10.1155/2014/473765. Accessed April 12, 2016:1-10.
8. Pietrzycka A, Kozka M, Urbanek T, Stpniewski M, Kucharzewski M,. Effect of micronized purified flavonoid fraction therapy on Endothelin-1 and TNF-alpha levels in relation to antioxidant enzyme balance in the peripheral blood of women with varicose veins. Curr Vasc Pharmacol. 2015; 13 (6): 801-808.
9. Urbanek T, Zbigniew K, Begier-Krasinska B, Baum E, Brborowicz A,. Sulodexide suppresses inflammation in patients with chronic venous insufficiency. Int Angiol. 2015; 34 (6): 589-96.
10. van Bemmelen PS, Bedford G, Beach K, Strandness DE,. Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning. J Vasc Surg. 1989; 10 (4): 425-431.
11. Mendoza E, Blattler W, Amsler F,. Great saphenous vein diameter at the saphenofemoral junction and proximal thigh as parameters of venous disease class. Eur J Vasc Endovasc Surg. 2013; 45 (1): 76-83.
12. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004; 40 (6): 1248-1252.
13. Rutherford RB, Padberg FT Jr, Comerota AJ, Kistner RL, Meissner MH, Moneta GL,. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg. 2000; 31 (6): 1307-1312.
14. Lippi G, Salvagno GL, Montagnana M, Guidi GC,. Short-term venous stasis influences routine coagulation testing. Blood Coagul Fibrinolysis. 2005; 16 (6): 453-458.
15. Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2012; 55 (5): 1449-1462.
16. Yang D, Vandongen YK, Stacey MC,. Variability and reliability of air plethysmographic measurements for the evaluation of chronic venous disease. J Vasc Surg. 1997; 26 (4): 638-642.
17. Cavezzi A, Labropoulos N, Partsch H, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs-UIP consensus document. Part II: anatomy. Eur J Vasc Endovasc Surg. 2006; 31 (3): 288-299.
18. Leach RD, Clemenson G, Morland M, Browse NL,. The relationship between venous pressure and vein wall fibrinolytic activity. J Cardiovasc Surg (Torino). 1982; 23 (6): 505-508.
19. Lipowsky HH,. The endothelial glycocalyx as a barrier to leukocyte adhesion and its mediation by extracellular proteases. Ann Biomed Eng. 2012; 40 (4): 840-848.
20. Coleridge Smith PD,. Deleterious effects of white cells in the course of skin damage in CVI. Int Angiol. 2002; 21 (2 suppl 1): 26-32.
21. Bogachev V, Golovanova OV, Sergeeva NA, Kuznetsov AN,. Participation of leucocytes in pathogenesis of primary forms of lower limb chronic venous disease. Angiol Sosud Khir. 2011; 17 (3): 71-75.
22. Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J,. Endogenous pro-thrombotic biomarkers from the arm and leg may not have the same value [published online May 29, 2015]. Phlebology. 2015.
23. Lattimer CR, Kalodiki E, Geroulakos G, et al. d -Dimer levels are significantly increased in blood taken from varicose veins compared with antecubital blood from the same patient. Angiology. 2015; 66 (9): 882-888.
24. Poredos P, Spirkoska A, Rucigaj T, Fareed J, Jezovnik MK,. Do blood constituents in varicose veins differ from the systemic blood constituents? Eur J Vasc Endovasc Surg. 2015; 50 (2): 250-256.
25. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S,. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011; 1813 (5): 878-888.
26. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996; 274 (5291): 1379-1383.
27. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15 (2): 103-113.
28. Mannello F, Raffetto JD,. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res. 2011; 3 (2): 149-158.
29. Saharay M, Shields DA, Georgiannos SN, et al. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 1998; 15 (4): 342-349.
30. Charo IF, Ransohoff RM,. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354 (6): 610-621.
31. Sayer GL, Smith PD,. Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. Eur J Vasc Endovasc Surg. 2004; 28 (5): 479-483.
32. Kim CS, Park HS, Kawada T, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond). 2006; 30 (9): 1347-1355.
33. Mukaida N, Harada A, Matsushima K,. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998; 9 (1): 9-23.
34. Minciullo PL, Catalano A, Mandraffino G, et al. Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch Immunol Ther Exp (Warsz). 2016; 64 (2): 111-126.
35. Saxena A, Khosraviani S, Noel S, Mohan D, Donner T, Hamad AR,. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2015; 74 (1): 27-34.
36. Jacob MP, Cazaubon M, Scemama A, et al. Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation. 2002; 106 (5): 535-538.
37. Lim CS, Gohel MS, Shepherd AC, Paleolog E, Davies AH,. Venous hypoxia: a poorly studied etiological factor of varicose veins. J Vasc Res. 2011; 48 (3): 185-194.
38. Krzysciak W, Kowalska J, Kozka M, Papie MA, Kwiatek WM,. Iron content (PIXE) in competent and incompetent veins is related to the vein wall morphology and tissue antioxidant enzymes. Bioelectrochemistry. 2012; 87: 114-123.
39. Sola Ldel R, Aceves M, Duenas AI, et al. Varicose veins show enhanced chemokine expression. Eur J Vasc Endovasc Surg. 2009; 38 (5): 635-641.
40. Eberhardt RT, Raffetto JD,. Chronic venous insufficiency. Circulation. 2014; 130 (4): 333-346.
41. Hoare MC, Nicolaides AN, Miles CR, et al. The role of primary varicose veins in venous ulceration. Surgery. 1982; 92 (3): 450-453.